SynthesisBMC cardiovascular disorders2025
Preventive percutaneous coronary intervention versus optimal medical therapy for vulnerable plaque: a meta-analysis.
Synthesis in BMC cardiovascular disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundThe effectiveness and safety of preventive percutaneous coronary intervention (PCI) on non-flow limiting vulnerable coronary plaque remain uncertain.
objectiveThe aim of this meta-analysis was to evaluate the impact of preventive PCI plus optimal medical therapy (OMT) in non-flow limiting vulnerable plaque on clinical outcomes compared with OMT alone.
methodWe searched PubMed, Embase, Web of Science (WOS), and the Cochrane from inception date to October 2024 for relevant studies which compared OMT and PCI plus OMT for non-flow limiting vulnerable plaques. Of the included studies, vulnerable plaques were defined as angiographically intermediate and non-flow limiting plaques with one or more of the following characteristics such as thin-cap fibroatheromas (TCFA), high lipid content, large plaque burden or small luminal area, although specific criteria differed among studies. The primary outcome was major adverse cardiac event (MACE). Pooled risk ratios (RR) were calculated using random effects models and heterogeneity was evaluated with the I
resultWe included 4 randomized clinical trials with 1,843 participants. The follow-up duration ranged from 6 to 25 months. Patients in PCI group had similar incidence of MACE compared with OMT group (RR = 0.38; 95% CI 0.10 to 1.45; P = 0.16). For individual components of MACE, there were no statistical differences in the incidence of all-cause death, myocardial infarction (RR = 0.55; 95% CI 0.05 to 6.51; P = 0.64; RR = 0.81; 95% CI 0.12 to 5.19; P = 0.82). However, compared with OMT group, PCI group experienced a reduction of clinically-driven revascularization and hospitalization for unstable or progressive angina (RR = 0.11; 95% CI: 0.03-0.40; P < 0.001; RR = 0.16; 95% CI: 0.05-0.56; P = 0.004).
conclusionIn patients with non-flow limiting vulnerable plaques, preventive PCI plus OMT showed a similar incidence of MACE but a reduction in the incidence of clinically-driven revascularization and hospitalizations for unstable or progressive angina, compared with OMT alone.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.